ONCS - OncoSec secures new patent in U.S.; shares up 8%

The USPTO has issued a new patent to OncoSec Medical (ONCS) covering its interleukin-12 (IL-12) based immunotherapy platform, including lead product candidate TAVO, and its proprietary EP gene delivery system.U.S. Patent No. 10,792,375, entitled Method for the Treatment of Malignancies, covers the use of intratumoral electroporation of DNA encoding interleukins to treat cancer and is significant because it is not specific to which type of immune-stimulatory interleukin can be used to treat a patient, nor is it limited to a particular type of cancer. "The new IP serves to secure our competitive position in the intratumoral oncology space and builds on our patent portfolio of growing scope," said Keir Loiacono, General Counsel and Vice President, Corporate Development at OncoSec.Shares are up 8% premarket.

For further details see:

OncoSec secures new patent in U.S.; shares up 8%